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We evaluated SR11237, a retinoid X receptor (RXR)-
specific compound, for its pharmacologic effects on cell dif-
ferentiation in F9 embryonal carcinoma cells and rhino 
mouse epidermis. SRl1237 can cause RXR/RXR homo-
dimers to form and transactivate a reporter gene containing a 
RXR-response element. We confirmed, using nuclear recep-
tor co-transfection assays in COS-l cells, that SR11237 is 
effective at trans activating a chloramphenicol acetyltransfer-
ase reporter gene through RXRs but not retinoic acid recep-
tors. When SR11237 was tested for its ability to modulate 
cell differentiation, it was inactive on F9 embryonal care i-
R etinoids are a class of compounds that regulate the growth and differentiation of normal and neoplastic cells in embryonic and adult tiSSues [1,2]. These pleio-tropic effects are mediated by two classes of nuclear receptors, retinoic acid receptors (RARs) and retinoid 
X receptors (RXRs). Akin to steroid hormone receptors, RARs and 
RXRs are ligand-activated transcription factors [3]. RARs and 
RXRs, in the absence of ligand, form a heterodimeric complex (see 
[4] for references). This heterodimeric complex binds to specific 
response elements (REs) in regulatory regions of target genes, and 
when ligand is present, it can modulate gene transcription. RXRs 
also form homodimeric complexes, but only when ligand is present 
[5]. These RXR/RXR homodimers activate target genes through 
unique REs that differ from RXR/RAR-heterodimer REs [6]. 
The effects of ligands on RARs and RXRs have been studied 
using co-transfection assays in cells with low levels of nuclear re-
ceptors. In such assays, receptors are overexpressed in the presence 
of a reporter plasmid containing an RAR RE or RXR RE. All-trans-
retinoic acid (t-RA) (Fig 1) activates only RXR/RAR heterodimers 
[3]. 9-cis-retinoic acid (9-cis-RA), a stereoisomer of t-RA, is pro-
posed to be the endogenous .ligand for RX~/RX.R homodimers 
l3,7,8]. However, 9-cis-RA bmds to RARs With high affimty and 
also acts as an agonist for RXR/RAR-gene transcription responses 
[3,8]. Some synthetic compounds are reported to be selective for 
inducing RXR/RXR homodimer formation and activating gene 
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noma cells and rhino mouse skin. Because differentiation in 
these systems is known to be regulated by RAR-specific 
compounds, such as all-trans-retinoic acid and (E)-4-[2-
(5,6,7 ,8-tetrah ydro-5,5,8 ,8-tetramethy 1-2-naphthaleny I )-1-
propenyl benzoic acid], our results with SRl1237 are com-
patible with the concept that classical .retinoid pleiotropic 
responses are mediated by RXR/RAR heterodimeric nuclear 
receptors rather than through RXR/RXR homodimers. Key 
words: retinoid receptors/heterodimers/homodimers/TTNPB. 
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transcription [9]; these compounds are inactive on RXR/RAR he-
terodimers [9]. Likewise, synthetic retinoids have been identified 
that activate RXR/RAR heterodimers and not RXR/RXR homo-
dimers [10] . 
The classical pleiotropic pharmacologic activities of t-RA on cell 
differentiation and proliferation can be replicated by synthetic com-
pounds that only activate RXR/RAR heterodimers, exemplified 
by (E) -4- [2- (5,6,7,8 - tetrahydro- 5,5,8,8 - tetramethyl- 2-naphtha-
lenyl)-l-propenyl] benzoic acid (TTNPB) (Fig 1). III vitro and ill 
Il ivo systems that are regulated by such retinoids express retinoid 
nuclear receptors constitutively. To more fully define the role of 
constitutively expressed retinoid nuclear receptors in mediating ret-
inoid pharmacologic responses, receptor-specific compounds can be 
used as tools to investigate such questions. To ascertain the potential 
role of RXR/RXR homodiniers in retinoid pharmacologic re-
sponses, we evaluated an RXR-specific compound, SRl1237 [9] 
(Fig 1), for its effects on cell differentiation and proliferation. We 
confirmed that SR11237 is an RXR-specific compound in co-trans-
fection assays; however, it does not exhibit the types of biologic 
activities in F9 embryonal carcinoma cells or the hairless rhino 
mouse that one observes with RXR/RAR agonists. 
MATERIALS AND METHODS 
Synthesis of SR11237 Friedel-Crafts acylation of 1,2,3,4-tetrahy-
dro-l,1 ,4,4-tetramethyl-naphthalene with 4-cyanobenzoylchloride yielded 
4-[(5,6,7,8 - tetrahydro - 5,5,8,8, - tetramethyl- 2 - naphthalenyl) carbonyl]-
benzonitrile (melting point 94-97 ' C). Acetalization of the latter com-
pound with ethylene glycol gave 4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetra-
methyl-2-naphthalenyl)-t,3-dioxolan-2-yl]-benzonitrile (melting point 
146' -148'C), which upon alka line hydrolysis resulted in SR11237 (4-[2-
(5,6,7,8 - tetrahydro - 5,5,8,8 - tetramethyl- 2 - naphthalenyl) -1,3 - dioxolan-
2-yl]-benzoic acid} (melting point 257 -259 ' C). 
RAR and RXR Transactivation Assays Compounds were tested as 
agonists on RARs or RXRs using a CAT reporter transactivation assay ill 
COS-l cel ls. Expression plasm ids coding for human RARa, RARP, RAR)' 
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Figure 1. Chemical structures for all-tralls-retinoic acid, TTNPB and 
SR11237. 
or RXRa (pSVL vectors, Pharmacia, Piscataway, NJ) were co-tra.risfected 
with TRE ,,-tk-CA T or RXREcRBP_II-tk-CA T reporter plasmIds mto 
COS-l cell~ along with a p-galactosidase expression vector (pCHll 0, Phar-
macia). Transfections were performed on cells plated in 162 cm' flasks using 
a synthetic cationic lipid transfection reagent (Transfectam, Promega, Mad-
ison WI) according to the manufacturer's instructions. The cells were kept 
in Dulbecco's Modified Eagle's Medium (DMEM) with 10% charcoal-
stripped fetal bovine serum for 24 h. Cells were subcultured into 24-well 
plates (2 X 10' cells per well). Te.st compounds were dissolved in etha1wl 
and diluted with DMEM contammg 10% charcoal-stnpped fetal bovme 
serum (final ethanol concentration of 0.1 %). Cells were incubated with test 
compounds for 24 h, media were then r~moved an.d cells were lysed \'mh 
0.25 M Tris-HCl, pH 7.8, by freeze thawll1g three times. Chloramphemcol 
acetyl transferase (CAT) activity was assayed using [3H]-acetyl .coenzy~e. A 
as substrate as described by Chauchereau et al [11]. p-galactosldase activity 
was measured using o-nitrophenyl-p-D-galactoside as substrate; the absorb-
ance of the product was measured at 415 nm. CAT activity was divided by 
p-galactosidase activity to normalize for transfection efficiency. 
F9 Embryonal Carcinoma Cells F9 embryonal carcinoma cells (gener-
ously provided by Dr. S. Strickland) were grown at 37°C in 5% carbon 
dioxidej95% air in DMEM with 10% heat-inactivated fetal bovine serum. 
RETINOID RECEPTOR AGONISTS 677 
For treatment with test compounds, cells were plated in 24-well culture 
plates (200 cells per well) in a total volume of 1.0 ml of media. Test com-
pounds were first dissolved in ethanol at 0.01 M and diluted 10 culture media 
(final ethanol concentration of 0.1 %). Forty-eight hours after plating, cells 
were treated with retinoid plus 1.0 mM dibutyryl cyclic adenosine mono-
phosphate and again at 24. 48, and 72 h. Twenty-four hours after the last 
treatment, media were removed and kept at 5 ° C. 
Laminin in media was measured by non-equilibrium enzyme-linked im-
munoadsorbent assay as described by Williams et al [12]. The primary anti-
body was rabbit anti-mouse laminin (EY Laboratories, San Mateo, CAl and 
the second antibody was goat anti-rabbit IgG coupled with horseradish 
peroxidase (Bio-Rad Laboratories, Melville, NY). Peroxidase activity was 
measured with o-phenylenediamine as substrate. Absorbance of tbe reaction 
product was measured at 490 nm in a UV",,, microplate reader (Molecular 
Devices, Menlo Park, CAl. Mouse laminin (Boehringer Mannheim, India-
napolis, IN) was used to construct standard curves. 
Rhino Mouse Evaluations 
Utri",/us Reductio,,: Male or female hairless rhino (1Irhhrh) mice (Jackson 
Laboratories, Bar Harbor, ME) were 8 -10 weeks old at the beginning of the 
study. Test compounds were dissolved in an ethanol: propylene glycol vehi-
cle (70: 30, v Iv) and applied topically (0.1 ml) to dorsal trunk skin once 
daily, five consecutive days per week for 2 weeks. Approximately 72 h 
following the last treatment, the mice were sacrificed by cervical dislocation. 
The treated dorsal trunk skin was removed and placed into 0.5% acetic acid 
for approximately 18 h at 4 ° C. After this, the epidermis was separated from 
the underlying dermis. The sheets of epidermis were processed by routine 
dehydration methods to permanent whole mounts for microscopic exami-
nation of utriculi diameters as described previously [13]. For each whole 
mount (one animal skin/slide) , the diameters of ten utriculi in five random 
fields (n = 50) were measured by image analysis (JAVA, Jandel Scientific, 
San Rafael, CAl. The mean utriculus diameter was calculated for each treat-
ment group. From this, the percent reduction of utriculus diameter com-
pared to the vehicle group was calculated. 
TrallSepidermal Water Loss (TEWL) : The rate of evaporation of water from 
rhino mouse skin was measured using a ServoMed evaporimeter (Kinna, 
Sweden). Readings were taken on the tenth treatment day, just before the 
last dosing with test compounds. 
Epidermal Keratiu aud Filaggrill Exprcssioll : Rhino mouse epidermal keratin 
and filaggrin expression was assessed by one-dimensional SDS - gel electro-
phoresis. The preparation of rhino mouse epidermis and extraction of epi-
dermal proteins was performed exactly as described previously [14]. Urea-
soluble material, which contains living layer keratins and filaggrin, was 
submitted to SDS-gel electrophoresis on 12.5% polyacrylamide precast 
gels, 10 cm X 10 cm (Daiichi MiniPlus Gel, Integrated Separation Systems, 
Natick, MA). Gels were stained with Coomasie blue (ISS Pro-Blue, Inte-
grated Separation Systems) to visualize protein bands. 
Skin Permeation If! lIitro skin permeation studies were conducted at 
32°C in modified Franz diffusion cells (9 mm opening, 10 ml volume, 
Crown Glass Inc. , Somerville, NJ) . Female dorsal trunk rhino mouse skin 
was mounted onto the diffusion cells (n = 3) and 100 III of a 0.1 % SR 1123 7 
solution (in ethanol: propylene glycol, 70: 3D, v Iv) was applied to the skin 
surfaces. The diffusion cells remained open to room air throughout the 
course of the study. Due to the low aqueous solubility of SR11237, 0.5% 
polysorbate 80 was added to the receptor solution to maintain adequate sink 
conditions. Based upon previous studies, it was determined that this receptor 
medium does not alter the skin permeability of this class of compounds. 
Receptor solutions were sampled (0.3 ml , with replacement) at 2, 4, 8, and 
24 h. At 24 h, skin samples were removed from the diffusion cells and 
washed twice with methanol and once with water. SR11237 was then 
extracted from the skin samples using a methanol : ethyl acetate (1 : 1) solu-
tion. SR11237 in samples was assayed by high-performance liquid chroma-
tography with UV detection. The chromatographic system used was a mo-
bile phase of acetonitrile: water (60: 40) with 0.1 % trifluoroacetic acid (flow 
rate: 2.0 ml/mill), a Spherisorb ODS-2 reverse-phase column, 5 J1.m 
(0.4 X 15 cm, Alltech) with UV detection at 240 nm. The detection limit 
for SR11237 with this method was 10 ng/ml. 
RESULTS 
RAR and RXR Transactivation Assays We first evaluated 
SR 11237 for its agonist activity on RARs and RXRs in COS-1 cells 
by co-transfectillg receptor expression vectors along with CAT re-
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Table I. Effects of SR11237 and t-RA on RAR Transactivation· 
Compound Concentration (nM) 
SR11237 1 
10 
100 
1000 
t-RA 100 
1000 
Cat Reporter Activity 
(% of Control)' 
RARa RARP RARy 
117 91 116 
164 125 123 
200 164 158 
201 242' 149 
1584' 1241' 572' 
2070' 1606' 713' 
• RAR expression plasmids for RARa, RARfJ, or RARy were co-transfected into 
COS-I cells with the TRE .. ,-tk-CAT reporter plasmid. 
• CAT reporter activity = CAT activity/p-galactosidase activity, where control (no 
test compound) = 100%. 
, Significantly different from control (no compound) at p = 0.05 level, Dunnett 
two-tai led test, based on comparison of normalized CAT activity values. Results shown 
arc from one experiment, n = 3 per concentration. 
porter plasmids. TREp,\-tk-CAT is activated by RXR/RAR hetero-
dimers or RXR/RXR homodimers, whereas RXREcl\.Bp_ll-tk-CAT 
is specific for RXR/RXR homodimers [5,9]. Table I shows results 
for RAR transactivation. SR11237 is weakly effective at activating 
the three RAR subtypes (C\', p, y), whereas t-RA strongly activates all 
three RARs. The degree of induction of CAT by t-RA through 
RARy is lower than RARC\' and RARp. The reasons for low trans-
activation ofRARy by t-RA are unclear, but this pattern of differen-
tial transactivation has been observed by others [15]. As shown in 
Table II, SR11237 dose-dependently activates RXRC\'. t-RA was 
also effective at activating RXRC\', but TTNPB was only slightly 
active on RXRC\'. t-RA is reported to activate RXRC\' by conversion 
in cells to 9-cis-RA [16,17] . 
We have thus confirmed that SRl1237 is a compound that acti-
vates RXR/RXR dimers. We also corroborated the findings of 
Mangelsdorf et al [10] showing that TTNPB is ineffective as a RXR 
agonist. 
F9 Embryonal Carcinoma Cells In the presence of cAMP, F9 
embryonal carcinoma cells are induced to terminally differentiate 
from a neoplastic state to parietal endoderm by retinoids [18]. Dur-
ing differentiation, F9 cells secrete various connective tissue pro-
teins; one of these, laminin, serves as a convenient biochemical 
marker of cell differentiation [12]. 
In contrast to t-RA, SR 11237 failed to induce differentiation of 
F9 cells to a parietal endoderm morphology, as assessed by light 
Table II. Effects of SR 1123 7, t-RA, and TTNPB 
on RXRa Transactivation· 
Compound 
SRl1237 
t-RA 
TTNPB 
Concentration 
(nM) 
0.1 
1 
10 
100 
1000 
1000 
1000 
CAT Reporter Activity 
(% of Control)' 
TRE,.rtk-CAT 
76 
105 
147 
524' 
606' 
780' 
262 
RXRECRBP_u-tk-CA T 
80 
108 
150 
345' 
436' 
462' 
121 
• RXRa expression pl asmid was co-transfected into COS-I cells with the TREp.,-tk-
CAT or RXREclUJ._II-tk-CAT reporter plasmids . 
• CAT reporter activity = CAT activity/p-galactosidase activity, where contrOJ'(no 
tcst compound) = 100%. 
, Significantly different from control (no comppound) at p = 0.05 level, Dunnett 
two-tai.led test, based on comparison of normalized CAT activity values. Results shown 
arc from onc experiment, n = 3 per concentration. 
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Table III. Effects of SR11237 and t-RA on F9 Embryonal 
Carcinoma Cells· 
Compound 
SR11237 
t-RA 
Concentration (nM) 
1 
10 
100 
1000 
0.1 
1 
10 
100 
1000 
Laminin Released (ng/mlb) 
-5 ± 10 
15 ± 22 
-8±4 
185 ± 35 
111 ± 39 
690 ± 108 
2154 ± 56 
2724 ± 387 
3330 ± 197 
• Cells were treated for 96 h with test compounds in the presence of 1.0 ruM dibutyryl 
cyclic adenosine monophosphate as described in Marerials alld Methods. 
• Calculated by subtracting the mean laminin release value (11 6.8 ng/ml) of the 
control group (dibutyryl cAMP treatment alone) from laminin release values of com-
pound plus cAMP groups. Results shown are mean ± SEM from one experiment, n = 3 
per concentration. 
microscopy. Table III also shows the lack of effect of SR11237 on 
laminin release at concentrations between 1 and 100 nM; a slight 
increase in laminin release occurred at 1000 11.M SR11237. With 
t-RA, laminin release was markedly increased in a dose-related 
manner, which plateaued between 100 and 1000 nM. 
Rhino Mouse Evaluation The hairless rhino mouse is an allelic 
mutant that exhibits abnormal hair follicle keratinization. The skin 
of these mice responds to retinoids with miniaturization of keratin-
filled hair follicles (utriculi) and changes in epidermal cytoskeleton 
protein expression [13,14]. Table IV shows that treatment of rhino 
mouse skin with t-RA dose-dependently reduces the size of horn-
filled utriculi. The rate of TEWL measured by evaporimetry was 
also enhanced by t-RA in a dose-dependent fashion (Table IV) . In 
contrast, SR11237 did not affect utriculi diameter and caused a 
small increase in TEWL only at 0.1 % (Table IV). 
In a second study, we evaluated the effects ofSRl1237 on keratin 
and filaggrin expression. In previous work we demonstrated that 
t-RA and TTNPB profoundly and specifically suppress filaggrin 
expression in rhino mouse epidermis [14] . Mice were dosed simi-
larly as for utriculus reduction except that during the second week, 
dosing was performed for four consecutive days and skin was re-
moved 24 h after the last dose. A piece of skin was also taken for 
hematoxylin and eosin-stained vertical histologic sections. 
Unlike 0.05% t-RA, 0.1 % SRl1237 did not suppress the expres-
sion of filaggritl in rhino mouse epidermis, as assessed by SDS - gel 
electrophoresis (data not shown). We also observed that keratin 
K17 was induced by t-RA, consistent with our previous findings 
[14]; however, K17 was not induced in epidermis ofSR11237-
treated skin. By histology, skin sections from 0.1% SRl1237-
treated mice were indistinguishable from vehicle-treated skin sec-
tions. Skin from these two treatment groups exhibited the 
characteristic abnormal epidermal architecture of rhino mice, with 
numerous hyperkeratinized follicular sacs (utriculi) and interfolli-
cular epidermis consisting of 2 - 4 epidermal cell layers. In contrast, 
skin treated with 0.05% t-RA had m.iniaturized follicles completely 
lacking in keratinized material and a hyperplastic epidermis consist-
ing of 5 - 8 epidermal cell layers. 
To verify that SRl1237 penetrates rhino mouse skin, we also 
assessed its permeation into and through excised skin. SR11237 
permeated through rhino mouse skin after an extended lag time. 
Only the 24-h samples from the receptor medium contained detect-
able SR11237 (mean ± SD = 4.4 ± l.ll1g/cm2). Results from the 
skin extraction indicated that 0.47 ± 0.19 I1g of SRl1237 was 
found in the skin after 24 h. These findings for permeation of 
SR11237 into and through rhino mouse skin are similar to that seen 
with other pharmacologically-active retino:ds (M. Corbo, unpub-
lished observations). Thus, these results exclude the possibility of 
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Table IV. Effects of SR11 237 and t-RA on Rhino Mouse Skin 
% Utriculus Reduction 
Treatment" Dose (%) Utriculus Diameter (um)b Versus Vehicle TEWL (gjm2j h)b 
Vehicle 118.9 ± 0.6 12.9 ± 1.2 
SRl1237 0.001 119.8 ± 1.1 -0.8 17.2±2.1 
0.01 118.3 ± 0.5 0.5 19.7 ±1.4 
0.1 119.0 ± 1.4 0 22.1 ± 2.4 
t-RA 0.0005 77.7 ± 1.4 34.7 23.3 ± 2.2 
0.005 51.1 ± 1.8 57.0 33.9 ± 5.9 
0.05 30.2 ± 1.3 74.6 56.8 ± 5.0 
• Mice were treated topically with test compounds for 2 weeks (five consecutive days per week) as described in Materials alld Methods . 
.. Results arc mean ± SEM from one experiment, n = 4 mice per treatment group. 
pharmacologic ~nactivity of SR11237 being due to its lack of per-
meation into rh1l10 mouse skll1. 
DISCUSSION 
We confirmed the specificity of SR 1123 7 as a compound that acti-
vates a RXRE, presumably by RXR/RXR homodimers [9] . 
SR11237, unlike t-RA or TTNPB, was far less effective as an ago-
nist on RXR/RAR heterodimer-activated gene responses. When 
SR 11237 was tested for its ability to modulate cell differentiation, it 
proved to be inactive on F9 embryonal carcinoma cells and rhino 
mouse skin. Although we did not evaluate TTNPB (an RAR-selec-
tive agonist) in these studies, previous work with the rhino mouse 
[14,19] and F9 cells [18,20] showsit to be a potent regulator of cell 
differentiation. Thus, our results gIve strong support to the concept 
that classic retinoid pleiotropic responses are mediated by RXR/ 
RAR-heterodimeric nuclear receptors rather than through RXR/ 
RXR homodimers. 
We used F9 cells and rhino mouse skin to evaluate SR11237 for 
pharmacologic. activity because they under.go ~arke.d changes in 
their differentiatIOn state when treated wIth vltamll1 A analogs 
(polyenes) as well as non-polyene synthetic retinoids [12-14, 
18 - 20]. Moreover, F9 cells and epidermal skin cells are reported to 
constitutively express mRNA for RARa and RARy [21 ,22] . Epider-
mal cells also express high levels ofRXRa [22]. Although it has not 
been shown directly, one can infer that F9 cells probably contain 
RXR for these cells to form RXR/RAR heterodimers and respond 
to RXR/RAR-specific agonists. 
A question that remains unanswered is whether or not RXR 
agonists like SRl1237 do induce RXR homodimers to form in F9 
cells or rhino mouse skin, even in the absence of observable pharma-
cologic effects. Constitutively expressed RXRs are present as heter-
odimeric complexes with RARs, vitamin D3, and thyroid hormone 
receptors [4] . In cases where the content of non-RXR nuclear recep-
tors exceeds RXRs, RXR agonists would have to cause RXR homo-
dimers to form from RXRs that are bound up in cells as hetero-
dimers. Transfection experiments suggest that this may be unlikely 
because overexpression of RARs in cells transfected with a RXR 
expression vector inhibits RXR-mediated transactivation of a 
RXREcRBP_lI-tk-CAT reporter plasmid [23]. 
Even if it is possible for RXR agonists to induce homodimer 
formation in cells that constitutively express RXRs, a pharmaco-
logic response is dependent on the presence of target genes that 
contain RXREs. CRBP-II, which is highly expressed in the small 
intestine, is one such target gene [23] . Apolipoprotein Al (apoA 1), 
the major protein component of high-density lipoprotein (ex-
pressed in the intestine and liver) also contains a RXRE in its 5'-reg-
ulatory gene region [24] . Thus, CRBP-II and apoAl expression 
could be used as RXR-specific markers to determine if RXR ago-
nists induce homodimer formation in target tissues. 
Whether or not RXR homodimers mediate a unique pleiotropic 
response that differs from RAR-induced pleiotropic effects remains 
to be determined. As proposed by Mangelsdorf and colleagues 
[7,10] , RXRs may subserve important physiologic roles in visceral 
tissues such as the liver, intestine and kidney. Pharmacologic studies 
with RAR and RXR-specific compounds should be useful in eluci-
dating the function of constitutively expressed RARs and RXRs in 
fetal and adult tissues. 
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ANNOUNCEMENT 
The International Symposium "Mast Cells in the Cytokine Network" will be held in Berlin, 
Germany on October 21- 22, 1994. 
The main subjects will be Mast Cell Ontogeny, Mast Cell Responses to Cytokines. Cytokine 
Secretion by Mast Cells, Pharmacological Modulation, and Clinical Significance. 
Prominent researchers in the field will present overview lectures on these topics. Participants 
submitting abstracts are given preference for attendance. Deadline for abstract submission is 
May 2,1994. 
For further information please contact the Congress Office, Frau Fuchs, Department of 
Dermatology, Freie Universitat Berlin, Universitatsklinikum Rudolf Virchow, Augusten-
burger Platz 1, D-13353 Berlin, Germany, Tel., (49-30)-4505-3131; Fax, (49-30)-4505-3131. 
